The Elipse Balloon, a swallowable gastric balloon for weight loss not requiring sedation, anesthesia or endoscopy: a pilot study with 12-month outcomes

Published:February 20, 2017DOI:



      The Elipse Balloon is a swallowable gastric balloon for weight loss that can be deployed without the use of endoscopy or anesthesia. This study aims to report on 12-month safety and efficacy outcomes.


      Private hospital, Athens, Greece.


      This was a prospective, nonrandomized open trial. Twelve patients between 18 and 64 years of age with a body mass index (BMI) of 27.0 to 40.0 kg/m2 were enrolled. The Elipse capsule is swallowed with water and its location in the stomach is confirmed by x-ray. All patients received diet and exercise counseling only during the therapy period (0–4 mo). Eight months later they were seen in clinic to assess 12-month outcomes.


      There were 7 (58.3%) females and 5 (41.7%) males. The mean age was 41 years, mean BMI was 35.9 kg/m2, mean weight was 103.5±15.8 kg, and mean waist circumference was 117.6±14.9 cm. All patients swallowed the balloon. Eleven (91.7%) balloons were filled and were included in subsequent analysis. All balloons were excreted safely, and no serious adverse events were reported. Accommodative symptoms were not severe and of very short duration. Mean excess weight loss percentage and total weight loss percentage were 50.2% and 14.6% at balloon excretion and 17.6% and 5.9% at 12 months, respectively. There was a statistically significant improvement in patients’ weight, BMI, body fat, waist circumference, diastolic blood pressure, HbA1C, cholesterol, thyroid stimulating hormone, aspartate transaminase, and alanine transaminase at balloon excretion. Quality of life was significantly improved at excretion and 12 months.


      This study is the first to demonstrate 12-month efficacy and performance outcomes of the Elipse Balloon.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fuller N.R.
        • Pearson S.
        • Lau N.S.
        • et al.
        An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study.
        Obesity (Silver Spring). 2013; 21: 1561-1570
        • Ponce J.
        • Woodman G.
        • Swain J.
        • et al.
        The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity.
        Surg Obes Relat Dis. 2015; 11: 874-881
        • Abu Dayyeh B.K.
        • Kumar N.
        • Edmundowicz S.A.
        • et al.
        ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies.
        Gastrointest Endosc. 2015; 82 (e5): 425-438
        • De Castro M.L.
        • Morales M.J.
        • Del Campo V.
        • et al.
        Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study.
        Obes Surg. 2010; 20: 1642-1646
        • Machytka E.
        • Chuttani R.
        • Bojkova M.
        • et al.
        Elipse, a procedureless gastric balloon for weight loss: a proof-of-concept pilot study.
        Obes Surg. 2016; 26: 512-516
        • Raftopoulos I.
        • Bernstein B.
        • O’Hara K.
        • Ruby J.A.
        • Chhatrala R.
        • Carty J.
        Protein intake compliance of morbidly obese patients undergoing bariatric surgery and its effect on weight loss and biochemical parameters.
        Surg Obes Relat Dis. 2011; 7: 733-742
        • Crosby R.D.
        • Kolotkin R.L.
        • Williams G.R.
        An integrated method to determine meaningful changes in health-related quality of life.
        J Clin Epidemiol. 2004; 57: 1153-1160
      1. Orbera Intragastric Balloon System. PMA P140008: FDA Summary of Safety and Effectiveness Data, Last accessed on 3/24/2017.
      2. ReShape Integrated Dual Balloon System. PMA P140012: FDA Summary of Safety and Effectiveness Data, Last accessed: 3/24/2017.
      3. Obalon Balloon System. PMA P160001: FDA Summary of Safety and Effectiveness Data, Last accessed: 3/24/2017.
        • Gaur S.
        • Levy S.
        • Mathus-Vliegen L.
        • Chuttani R.
        Balancing risk and reward: a critical review of the intragastric balloon for weight loss.
        Gastrointest Endosc. 2015; 81: 1330-1336
        • Imaz I.
        • Martinez-Cervell C.
        • Garcia-Alvarez E.E.
        • Sendra-Gutierrez J.M.
        • Gonzalez-Enriquez J.
        Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis.
        Obes Surg. 2008; 18: 841-846
        • Mion F.
        • Ibrahim M.
        • Marjoux S.
        • et al.
        Swallowable Obalon® Gastric Balloons as an aid for weight loss: a pilot feasibility study.
        Obes Surg. 2013; 23: 730-733
        • Barmparas G.
        • Branco B.C.
        • Schnüriger B.
        • Lam L.
        • Inaba K.
        • Demetriades D.
        The incidence and risk factors of post-laparotomy adhesive small bowel obstruction.
        J Gastrointest Surg. 2010; 14: 1619-1628
        • Angenete E.
        • Jacobsson A.
        • Gellerstedt M.
        • Haglind E.
        Effect of laparoscopy on the risk of small-bowel obstruction: a population-based register study.
        Arch Surg. 2012; 147: 359-365